ArticleClinical epigenetics2026
β-Hydroxybutyrate upregulates hepatic histone β-hydroxybutyrylation modification, promotes the expression of PPARα, and alleviates the hepatic steatosis in MASLD.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) stands as the most widespread chronic liver disorder globally. Histone β-hydroxybutyrylation (Kbhb)-a novel post-translational modification of histones driven by β-hydroxybutyrate (BHB)-has recently been recognized as a key epigenetic modulator. Our study aimed to explore how BHB influences the expression of hepatic lipid metabolism-associated genes in MASLD, and to determine whether histone Kbhb acts as the mechanistic mediator underlying these effects.
methodsFor in vivo experiments, db/db mice fed a high-fat diet were utilized as the MASLD model. Following BHB intervention, changes in glycolipid metabolism and lipid accumulation in liver were assessed. Hepatic expression of lipid oxidation-related genes (e.g., PPARα) was quantified via qPCR; hepatic Pan-Kbhb and H3K9bhb levels were detected using immunohistochemistry and immunofluorescence. For in vitro experiments, a palmitic acid (PA)-induced AML12 hepatocyte model was established. After BHB treatment, intracellular lipid accumulation was visualized via Oil Red O and BODIPY staining; PPARα and downstream lipid oxidation gene expression was measured by qPCR and Western blotting. Total protein and histone Kbhb were evaluated using immunofluorescence and Western blotting.
resultsBHB effectively mitigated lipid accumulation in the livers of db/db mice and PA-induced AML12 cells, while upregulating PPARα and its downstream lipid oxidation-related target genes. Simultaneously, BHB elevated total protein Kbhb and histone H3K9bhb modifications in hepatic cells. Critically, blocking Kbhb (via A485, an inhibitor of the acyltransferase P300, or an acyl-CoA synthetase 2 inhibitor) led to significant downregulation of PPARα and its target gene expression.
conclusionBHB alleviates lipid accumulation in the liver of MASLD by promoting the expression of PPARα and its downstream lipid oxidation-related genes in the hepatocytes, which is associated with histone Kbhb modification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.